Natvarlal Patel, MD
Urology · Norfolk, NENPI 1710196746
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (47.9%), food and beverage and education — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Coloplast at 58.3% of the total. Reporting peaked in 2022 at $1,097 and has fallen 98.4% since, to $18 in 2025. That places this record below the midpoint for urology clinicians in NE, where the typical reported total is $2,774.
Across 29 payments — averaging $62.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$1K
- Astellas Pharma US Inc$273
- E.r. Squibb & Sons, L.L.C.$129
- Dornier Medtech America, Inc$58
- AstraZeneca$55
- AbbVie$48
- plus $194 from 9 others
What the payments were for
- Travel & lodging$86948%
- Food & beverage$75442%
- Education$19010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 9 | $1,057 |
| Astellas Pharma US Inc | 4 | $273 |
| E.r. Squibb & Sons, L.L.C. | 1 | $129 |
| Dornier Medtech America, Inc | 1 | $58 |
| AstraZeneca | 1 | $55 |
| AbbVie | 3 | $48 |
| Boston Scientific | 1 | $33 |
| Merck | 1 | $31 |
| Johnson & Johnson | 2 | $26 |
| Tolmar, Inc. | 1 | $25 |
| Myovant Sciences Inc. | 1 | $19 |
| Dendreon Pharmaceuticals LLC | 1 | $18 |
| Convatec Inc. | 1 | $15 |
| Amgen | 1 | $14 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,813 in reported general payments places this provider in the 40th percentile of 79 urology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Citrate ErPotassium Citrate | 44 | $2,607 |
| Tamsulosin Hcl | 98 | $907 |
| Bicalutamide | 43 | $810 |
| Finasteride | 66 | $769 |
| Bethanechol Chloride | 17 | $491 |
| Atorvastatin Calcium | 11 | $267 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 11 | $149 |
| Allopurinol | 16 | $141 |
| Omeprazole | 16 | $122 |
| Amlodipine Besylate | 25 | $80 |
| Cephalexin | 13 | $74 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 19 | $51 |
| Ciprofloxacin Hcl | 12 | $16 |
Paid to pharmacies, not to this prescriber.
Other urology in Norfolk
- John BishayOmaha$138K
- Garrett PohlmanKearney$123K
- Rebecca McCreryOmaha$71K
- Judson DaviesOmaha$67K
- Stefanie BolteOmaha$59K
- Antonio BeltranLincoln$51K
- Michael FeloneyOmaha$29K
- Ansar KhanFremont$15K
- Don HensleeFairbury$15K
- Thomas BrushLincoln$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.